BRKRP // Bruker Corporation 6.375% Mandatory Convertible Preferred Stock Series A
ANR <GO> NASDAQ CIK 0001109354 ↗ Health Care • Biotechnology: Laboratory Analytical Instruments
$454.20 ▼ -1.23
(-0.27%)
MKT CAP: $69.20B • VOL: 16.2K
52W L $264 52W H $485
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$382
MEDIAN
$509
MEAN
$518
HIGH
$618
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BRKRP TAPE
BRKRP // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $549.58 | $522.33 | 2025-02-14 | $413.32 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $572.29 | $535.96 | 2025-02-06 | $426.95 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $517.79 | $499.62 | 2025-01-29 | $436.03 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $463.28 | — | 2025-01-17 | $445.12 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $399.70 | $431.49 | 2025-01-09 | $404.24 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $540.50 | $472.37 | 2024-12-18 | $395.15 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $440.57 | $458.74 | 2024-12-04 | $422.41 | -4.3% | 48% | C |